Impact of maintenance of postoperative performance status on survival in elderly patients over 70 with high-grade astrocytoma

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide

for glioblastoma. N Engl J Med. 2005;352(10):987–996.

2. Heiland DH, Haaker G, Watzlawick R, et al. One decade of glioblastoma multiforme surgery in 342 elderly

patients: what have we learned? J Neurooncol. 2018;140(2):385–391.

3. Palmer JD, Bhamidipati D, Mehta M, et al. Treatment recommendations for elderly patients with newly

diagnosed glioblastoma lack worldwide consensus. J Neurooncol. 2018;140(2):421–426.

4. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707–715.

5. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus

hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised,

phase 3 trial. Lancet Oncol. 2012;13(9):916–926.

6. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly

diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet

Oncol. 2008;9(1):29–38.

7. Yin AA, Zhang LH, Cheng JX, et al. The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis. PLoS One. 2014;9(1):e85102.

8. Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients

with glioblastoma. N Engl J Med. 2017;376(11):1027–1037.

9. Gallego PL, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma

and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29(22):3050–3055.

10. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous

system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 2015;17(suppl 4):iv1–iv62.

11. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma

multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–198.

12. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas:

response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972.

13. Watanabe R, Nakasu Y, Tashiro H, et al. O6-methylguanine DNA methyltransferase expression in tumor

cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with

primary glioblastoma. Brain Tumor Pathol. 2011;28(2):127–135.

14. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow

Transplant. 2013;48(3):452–458.

15. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide

vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–2543.

16. Babu R, Komisarow JM, Agarwal VJ, et al. Glioblastoma in the elderly: the effect of aggressive and modern

therapies on survival. J Neurosurg. 2016;124(4):998–1007.

17. Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE. Glioblastoma in the elderly: the Memorial

Sloan-Kettering Cancer Center Experience (1997–2007). Cancer. 2009;115(16):3758–3766.

18. Morgan ER, Norman A, Laing K, Seal MD. Treatment and outcomes for glioblastoma in elderly compared

with non-elderly patients: a population-based study. Curr Oncol. 2017;24(2):e92–e98.

19. Tanaka S, Meyer FB, Buckner JC, Uhm JH, Yan ES, Parney IF. Presentation, management, and outcome

of newly diagnosed glioblastoma in elderly patients. J Neurosurg. 2013;118(4):786–798.

20. Tsang DS, Khan L, Perry JR, et al. Survival outcomes in elderly patients with glioblastoma. Clin Oncol

(R Coll Radiol). 2015;27(3):176–183.

543

The elderly with high grade astrocytoma

21. Karsy M, Yoon N, Boettcher L, et al. Surgical treatment of glioblastoma in the elderly: the impact of

complications. J Neurooncol. 2018;138(1):123–132.

22. D’Amico RS, Cloney MB, Sonabend AM, et al. The safety of surgery in elderly patients with primary and

recurrent glioblastoma. World Neurosurg. 2015;84(4):913–919.

23. Di Cristofori A, Zarino B, Fanizzi C, et al. Analysis of factors influencing the access to concomitant

chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume. J

Neurooncol. 2017;134(2):377–385.

24. Amsbaugh MJ, Yusuf MB, Gaskins J, Burton EC, Woo SY. Patterns of care and predictors of adjuvant

therapies in elderly patients with glioblastoma: an analysis of the National Cancer Data Base. Cancer.

2017;123(17):3277–3284.

25. Gately L, Collins A, Murphy M, Dowling A. Age alone is not a predictor for survival in glioblastoma. J

Neurooncol. 2016;129(3):479–485.

26. Huang J, Samson P, Perkins SM, et al. Impact of concurrent chemotherapy with radiation therapy for elderly

patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. J Neurooncol.

2017;131(3):593–601.

27. Gorlia T, Stupp R, Brandes AA, et al. New prognostic factors and calculators for outcome prediction in

patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II

clinical trials. Eur J Cancer. 2012;48(8):1176–1184.

28. Zanello M, Roux A, Ursu R, et al. Recurrent glioblastomas in the elderly after maximal first-line

treatment: does preserved overall condition warrant a maximal second-line treatment? J Neurooncol.

2017;135(2):285–297.

...